Program
bictegravir
Also written as “B/F/TAF”, “Bictegravir” and “BIC/LEN FDC”.
Its studies are mostly in Coinfection · Kidney Failure, Chronic · Mesothelioma, Malignant, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 238 open or running | phase 4since Oct 23, 2023 | Oct 23, 2014 | Aug 2027phase 2 · NCT07645287 |
| AGC Biologics | 10 open or running | phase 3since Mar 17, 2010 | Mar 17, 2010 | none ahead |
| Merck | 10 open or running | phase 1since Apr 8, 2026 | Apr 8, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Mar 17, 2010.
- Aug 13, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03631732 · 496 enrolled · United States
- May 21, 2019Phase 1 study in HIV-1-infectionGilead Sciences · NCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
- Oct 28, 2019Phase 2 study in HIV-1-infectionGilead Sciences · NCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
- Aug 5, 2022Phase 3 study in HIV-1-infectionGilead Sciences · NCT05502341 · 689 enrolled · United States, Argentina, Australia and more
- Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
- Mar 20, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06333808 · 577 enrolled · United States, Argentina, Australia and more
- Jul 29, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06532656 · 75 enrolled · United States, Argentina, Italy and more
- Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
- Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
- Apr 8, 2026Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT07532304 · 16 enrolled · United States
- Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more
- Sep 29, 2026Primary completion moved from 2026-11 to 2030-07Date moved laterphase 3 · +44 months · NCT06532656
- Oct 26, 2026Phase 4 study in HIV-1 InfectionGilead Sciences · NCT07908446 · 400 planned
Ahead
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
- Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
- Jul 2028Primary completion: phase 4 study in HIV-1 InfectionGilead Sciences · NCT07908446
- Jul 2030Primary completion: phase 3 study in HIV-1-infectionGilead Sciences · NCT06532656
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07908446HIV-1 Infection | 4 | Not yet recruiting | Gilead Sciences | Jul 2028 | 400 |
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Gilead Sciences | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Gilead Sciences | Aug 2027 | 175 |
| NCT07532304Healthy · United States | 1 | Completed | Merck | Jul 23, 2026 | 16 |
| NCT07055451HIV-1-infection · United States, South Africa | 1 | Active, not recruiting | Gilead Sciences | Mar 2028 | 16 |
| NCT06630286HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 17, 2026 | 609 |
| NCT06532656HIV-1-infection · United States, Argentina, Italy and more | 3 | Active, not recruiting | Gilead Sciences | Jul 2030 | 75 |
| NCT06333808HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Oct 27, 2025 | 577 |
| NCT06104306HIV-1-infection · United States, Canada, France | 4 | Completed | Gilead Sciences | Jan 29, 2025 | 33 |
| NCT05502341HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Sep 29, 2025 | 689 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 5, 2021 | 183 |
| NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand | 1 | Completed | Gilead Sciences | Jul 21, 2022 | 62 |
| NCT03631732HIV-1 Infection · United States | 3 | Completed | Gilead Sciences | Aug 12, 2019 | 496 |
| NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more | 3 | Completed | Gilead Sciences | Feb 25, 2022 | 244 |
| NCT03405935HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Nov 20, 2018 | 86 |
| NCT03110380HIV-1-infection · United States, Austria, Canada and more | 3 | Completed | Gilead Sciences | Dec 4, 2018 | 567 |
| NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more | 3 | Completed | Gilead Sciences | Oct 9, 2017 | 472 |
| NCT02607956HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 12, 2017 | 657 |
| NCT02607930HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | May 9, 2017 | 631 |
| NCT02603120HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 9, 2017 | 567 |
| NCT02600819Kidney Failure, Chronic · United States, Austria, France and more | 3 | Completed | Gilead Sciences | Sep 29, 2017 | 55 |
| NCT02397694HIV-1 Infection · United States | 2 | Completed | Gilead Sciences | Nov 30, 2015 | 98 |
| NCT02400307HIV · United States, New Zealand | 1 | Completed | Gilead Sciences | Jul 6, 2015 | 19 |
| NCT02275065HIV-1 Infection · United States | 1 | Completed | Gilead Sciences | Jan 23, 2015 | 23 |
| NCT01098266Mesothelioma, Malignant · United States, Belgium, Canada and more | 3 | Completed | AGC Biologics | Apr 29, 2014 | 400 |
How it is read
Names in the registry
- “B/F/TAF”, 16 entries
- “Bictegravir”, 3 entries
- “BIC/LEN FDC”, 2 entries
- “Bictegravir/Lenacapavir (BIC/LEN) FDC”, 2 entries
- “Bictegravir/Lenacapavir”, 1 entry
Conditions, from the studies’ own filings
- Coinfection, 1 study
- Kidney Failure, Chronic, 1 study
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.